Kuros Biosciences AG
Other OTCTotal Valuation
Kuros Biosciences AG carries a market capitalization of 975.45M, placing it among publicly traded companies globally. Its enterprise value stands at -11.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 975.45M |
| Enterprise Value | -11.53M |
Share Statistics
Kuros Biosciences AG currently has 351,157.00 shares outstanding.
| Shares Outstanding | 351,157.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.85, and the price-to-book ratio stands at 0.00.
| PE Ratio | N/A |
| PS Ratio | 0.85 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.20 |
| P/FCF Ratio | -0.04 |
| P/OCF Ratio | -0.04 |
Enterprise Valuation
| EV / Sales | 7.41 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Kuros Biosciences AG maintains a current ratio of 6.94, meaning it holds 6.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 649.34, indicating elevated leverage, while an interest coverage ratio of -2.96 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.94 |
| Quick Ratio | 6.86 |
| Debt / Equity | 649.34 |
| Debt / EBITDA | -1.18 |
| Interest Coverage | -2.96 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -86.96 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Kuros Biosciences AG's stock has declined approximately -14.38948% over the past 52 weeks. The 50-day moving average sits at 26.84, while the 200-day moving average is 32.88.
| Beta (5Y) | N/A |
| 52-Week Price Change | -14.38948% |
| 50-Day Moving Average | 26.84 |
| 200-Day Moving Average | 32.88 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kuros Biosciences AG generated 1.00M in revenue and converted that into -30.82M in net income, yielding earnings per share of -111.10. EBITDA reached -23.27M, while operating income came in at -23.27M.
| Revenue | 1.00M |
| Gross Profit | -11.95M |
| Operating Income | -23.27M |
| Pretax Income | -30.82M |
| Net Income | -30.82M |
| EBITDA | -23.27M |
| EBIT | -23.27M |
| Earnings Per Share (EPS) | -111.10 |
Balance Sheet
Kuros Biosciences AG holds 39.85M in cash and equivalents against 27.47M in total debt, resulting in a net debt position of -12.38M. Total book value stands at -267.81M, with working capital of 34.53M providing operational flexibility.
| Cash & Cash Equivalents | 39.85M |
| Total Debt | 27.47M |
| Net Debt | -12.38M |
| Equity (Book Value) | -267.81M |
| Book Value Per Share | -965.22 |
| Working Capital | 34.53M |
Cash Flow
Kuros Biosciences AG produced -19.17M in operating cash flow over the past twelve months.
| Operating Cash Flow | -19.17M |
| Capital Expenditures | N/A |
| Free Cash Flow | -19.17M |
| FCF Per Share | -69.09 |
Margins
Kuros Biosciences AG operates with a gross margin of -1,194.90, reflecting its pricing power and cost economics. The operating margin of -2,326.60 and net profit margin of -3,082.50 provide insight into operational efficiency.
| Gross Margin | -1,194.90 |
| Operating Margin | -2,326.60 |
| Pretax Margin | -3,082.50 |
| Profit Margin | -3,082.50 |
| EBITDA Margin | -2,326.60 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -3,563.16 |
| FCF Yield | -2,266.96 |
Stock Splits
Kuros Biosciences AG's most recent stock split took place on October 12, 2020 with a 200:217 split ratio.
| Last Split Date | 10/12/2020 |
| Split Ratio | 200:217 |
Scores
Kuros Biosciences AG posts an Altman Z-Score of -10.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -10.20 |